WO1996005867A3 - Compositions - Google Patents

Compositions Download PDF

Info

Publication number
WO1996005867A3
WO1996005867A3 PCT/GB1995/001969 GB9501969W WO9605867A3 WO 1996005867 A3 WO1996005867 A3 WO 1996005867A3 GB 9501969 W GB9501969 W GB 9501969W WO 9605867 A3 WO9605867 A3 WO 9605867A3
Authority
WO
WIPO (PCT)
Prior art keywords
physiologically tolerable
manganese
compositions
hydroxy
uptake promoter
Prior art date
Application number
PCT/GB1995/001969
Other languages
French (fr)
Other versions
WO1996005867A2 (en
Inventor
Klaes Golman
Goeran Pettersson
Arne Berg
Jo Klaveness
Pal Rongved
Peter Leander
Ib Leunbach
Wolfgang Gunther
Original Assignee
Nycomed Imaging As
Cockbain Julian
Klaes Golman
Goeran Pettersson
Arne Berg
Jo Klaveness
Pal Rongved
Peter Leander
Ib Leunbach
Wolfgang Gunther
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9416768A external-priority patent/GB9416768D0/en
Priority claimed from GB9416767A external-priority patent/GB9416767D0/en
Application filed by Nycomed Imaging As, Cockbain Julian, Klaes Golman, Goeran Pettersson, Arne Berg, Jo Klaveness, Pal Rongved, Peter Leander, Ib Leunbach, Wolfgang Gunther filed Critical Nycomed Imaging As
Priority to NZ291479A priority Critical patent/NZ291479A/en
Priority to AU32620/95A priority patent/AU688565B2/en
Priority to EP95929155A priority patent/EP0776219A2/en
Priority to JP8507869A priority patent/JPH10504559A/en
Priority to CA002197466A priority patent/CA2197466A1/en
Publication of WO1996005867A2 publication Critical patent/WO1996005867A2/en
Publication of WO1996005867A3 publication Critical patent/WO1996005867A3/en
Priority to FI970667A priority patent/FI970667A/en
Priority to NO970747A priority patent/NO970747D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

There is provided a contrast medium composition comprising a physiologically tolerable manganese compound, an uptake promoter and a physiologically tolerable carrier or excipient, having a manganese concentration of at least 0.3mM or being in a dosage unit form containing at least 300 νmol manganese, wherein the uptake promoter comprises a physiologically tolerable reducing compound containing an α-hydroxy ketone group, a physiologically tolerable acid containing α- and/or β-hydroxy or amino groups, or a salt thereof, and/or vitamin D. Such compositions are particularly suitable for imaging of the liver.
PCT/GB1995/001969 1994-08-18 1995-08-18 Compositions WO1996005867A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
NZ291479A NZ291479A (en) 1994-08-18 1995-08-18 Contrast medium containing a manganese compound, an uptake promoter and carrier for use in mri
AU32620/95A AU688565B2 (en) 1994-08-18 1995-08-18 Compositions
EP95929155A EP0776219A2 (en) 1994-08-18 1995-08-18 Compositions
JP8507869A JPH10504559A (en) 1994-08-18 1995-08-18 Composition
CA002197466A CA2197466A1 (en) 1994-08-18 1995-08-18 Compositions
FI970667A FI970667A (en) 1994-08-18 1997-02-17 compositions
NO970747A NO970747D0 (en) 1994-08-18 1997-02-18 compositions

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9416767.3 1994-08-18
GB9416768.1 1994-08-18
GB9416768A GB9416768D0 (en) 1994-08-18 1994-08-18 Compositions
GB9416767A GB9416767D0 (en) 1994-08-18 1994-08-18 Compositions
US46287395A 1995-06-05 1995-06-05
US08/465,100 US5716598A (en) 1994-08-18 1995-06-05 Contrast medium for magnetic resonance imaging using physiologically tolerable manganese compound

Publications (2)

Publication Number Publication Date
WO1996005867A2 WO1996005867A2 (en) 1996-02-29
WO1996005867A3 true WO1996005867A3 (en) 1996-07-11

Family

ID=56289650

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1995/001969 WO1996005867A2 (en) 1994-08-18 1995-08-18 Compositions

Country Status (1)

Country Link
WO (1) WO1996005867A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK81095A (en) * 1995-07-11 1997-01-12 Henrik S Thomsen Oral MR contrast agent for liver and upper intestinal tract
WO1998011922A2 (en) * 1996-02-16 1998-03-26 Nycomed Imaging As Method
GB9619758D0 (en) * 1996-09-23 1996-11-06 Nycomed Imaging As Method
GB9619759D0 (en) * 1996-09-23 1996-11-06 Nycomed Imaging As Method
EP0988864A1 (en) * 1998-09-23 2000-03-29 Luboldt, Wolfgang, Dr.med. Dipl.-Phys. Contrast agent for magnetic resonance tomography
AU2003210850A1 (en) 2002-02-05 2003-09-02 Bristol-Myers Squibb Company N-substituted3-hydroxy-4-pyridinones and pharmaceuticals containing thereof
SE527491C2 (en) 2003-12-19 2006-03-21 Cmc Contrast Ab Contraceptive composition for magnetic resonance tomography for oral administration
WO2011003818A2 (en) 2009-07-06 2011-01-13 Cmc Contrast Ab Diagnostic method
US20220257802A1 (en) 2019-06-07 2022-08-18 Ascelia Pharma AB Compressed solid composition for mri
WO2023213916A1 (en) 2022-05-05 2023-11-09 Ascelia Pharma AB Mri composition and its use in nonfasting subjects

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004622A1 (en) * 1986-02-06 1987-08-13 Albion Laboratories, Inc. Amino acid chelated compositions for delivery to specific biological tissue sites
EP0401096A1 (en) * 1989-05-24 1990-12-05 Laboratoires Lucien Agents and complexes of ion Mg++ facilitating absorption of magnesium in a human or animal organism, and pharmaceutical or dietetic compositions useful for the administration of magnesium in a human or animal organism
EP0524633A2 (en) * 1991-07-24 1993-01-27 Beres Export-Import Rt. Pharmaceutical composition suitable for influencing the reticuloendothelial system
WO1993006811A2 (en) * 1991-09-30 1993-04-15 Cockbain, Julian, Roderick, Michaelson Vanadium compositions
US5292729A (en) * 1992-08-14 1994-03-08 Albion International, Inc. II-bond aromatic vitamin chelates

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004622A1 (en) * 1986-02-06 1987-08-13 Albion Laboratories, Inc. Amino acid chelated compositions for delivery to specific biological tissue sites
EP0401096A1 (en) * 1989-05-24 1990-12-05 Laboratoires Lucien Agents and complexes of ion Mg++ facilitating absorption of magnesium in a human or animal organism, and pharmaceutical or dietetic compositions useful for the administration of magnesium in a human or animal organism
EP0524633A2 (en) * 1991-07-24 1993-01-27 Beres Export-Import Rt. Pharmaceutical composition suitable for influencing the reticuloendothelial system
WO1993006811A2 (en) * 1991-09-30 1993-04-15 Cockbain, Julian, Roderick, Michaelson Vanadium compositions
US5292729A (en) * 1992-08-14 1994-03-08 Albion International, Inc. II-bond aromatic vitamin chelates

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BELL, JANET G. ET AL: "Higher retention of manganese in suckling than in adult rats is not due to maturational differences in manganese uptake by rat small intestine", J. TOXICOL. ENVIRON. HEALTH, VOL. 26, NO. 4, PAGE(S) 387-98 *
GERARD C ET AL: "Thermodynamic stability of complexes of kojic acid an.alpha.-keto enol, with divalent cations: manganese, cobalt, nickel, copper and zinc", BULL. SOC. CHIM. FR., 1975,, NO. 11-12, PT. 1, PAGE(S) 2404-8 *
GERARD, CHRISTIAN: "Studies of neutral complexes of kojic acid and maltol with divalent manganese, cobalt, nickel, copper, and zinc cations", BULL. SOC. CHIM. FR., no. 11-12, pages 451 - 456 *
GIURGEA, RODICA ET AL: "Effects of acute manganese treatment on biochemical parameters in chickens", STUD. CERCET. BIOL., SER. BIOL. ANIM., VOL. 44, NO. 2, PAGE(S) 135-7 *
JOHNSON, PHYLLIS E. ET AL: "Effects of copper, iron, and ascorbic acid on managanese availability to rats", PROC. SOC. EXP. BIOL. MED., VOL. 199, NO. 4, PAGE(S) 470-80 *
LONNERDAL B: "Trace element absorption in infants as a foundation to setting upper limits for trace elements in infant formulas.", J NUTR, DEC 1989, VOL. 119, NO. 12 SUPPL, PAGE(S) 1839-44;DISCUSSION 1845 *
PETROLA R: "Stability of yttrium(III) complexes of substituted 3-hydroxy-4H-pyran-4-ones in aqueous solution", FINN. CHEM. LETT., 1986, VOL. 13, NO. 5, PAGE(S) 129-35, XP000565614 *
RUBIN D.L. ET AL: "Formulation of radiographically detectable gastrointestinal contrast agents for magnetic resonance imaging: Effects of a barium sulfate additive on MR contrast agent effectiveness", MAGN. RESON. MED., 1992, VOL. 23, NO. 1, PAGE(S) 154-165, XP000250035 *
SEABORN, CAROL D. ET AL: "Chromium and chronic ascorbic acid depletion effects on tissue ascorbate, manganese, and 14C retention from 14C-ascorbate in guinea pigs", BIOL. TRACE ELEM. RES., VOL. 41, NO. 3, PAGE(S) 279-94 *
STAMPFLI R ET AL: "Thermodynamics of Kojate complexes of the lanthanides", J. COORD. CHEM., 1972, VOL. 1, NO. 3, PAGE(S) 173-7, XP000565612 *

Also Published As

Publication number Publication date
WO1996005867A2 (en) 1996-02-29

Similar Documents

Publication Publication Date Title
CA2094540A1 (en) Orally-ingestible nutrition compositions having improved palatability
GB8524275D0 (en) Pharmaceutical & dietary compositions
AU5739594A (en) Recirculation plural pump cassettes for solution compounding
EP0684040A3 (en) Skin treatment composition
WO1996005867A3 (en) Compositions
WO1999050268A3 (en) Substituted indolealkanoic acids
CA2277832A1 (en) Cyclic peptides that bind to urokinase-type plasminogen activator receptor
CA2307820A1 (en) Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
IE870610L (en) Hydroxylamine derivatives.
EP0751183A3 (en) A polyester composition used for thermoshrinkable films
AU586892B2 (en) Pharmaceutical and dietary composition
CA2203936A1 (en) Boronic ester and acid compounds, synthesis and uses
CA2125644A1 (en) Pharmaceutical compositions containing the salts of s(+)-2-(4-isobutylphenyl)propionic acid with basic aminoacids
AU4835396A (en) Composition containing nucleic acids, preparation and use
PL297727A1 (en) Method of isolating and purifying fatty acids and hydroxy fatty acids
IL130524A0 (en) Stable liquid interferon formulations a kit containing the same and a process for stabilizing the same
DE3676883D1 (en) COMPOUNDS OF FORMULA 2 '- ((((SUBSTITUTED) PHENYL) - (SUBSTITUTED) AMINO) CARBONYL) - (1,1'-BIPHENYL) -2-CARBONIC ACID, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND A METHOD FOR THE PRODUCTION THEREOF.
WO2000015179A3 (en) Cosmetic composition
GEP20012516B (en) Tricyclic Compounds Having Activity Specific for Integring, Particularly , avB3 Integrins, Method for Preparation the Same as Drugs and Pharmaceutical Composition Containing Same
EP0370481A3 (en) Pharmaceutical preparations for the enhanced resorption of antibacterial compounds
EP0228192A3 (en) Renin-inhibitory oligopeptides, their preparation and use
IL81800A0 (en) 1,2,3,4-tetrahydro-6-substituted-4-aryl(or heterocyclo)-3-((substituted amino)carbonyl)-2-thioxo(or oxo)-5-pyrimidine-carboxylic acids and esters and pharmaceutical compositions containing the same
EP0795604A3 (en) Strains of bacteria with altered metabolism of bile acids and their use
JPS55138391A (en) New synthetic method of peptide derivative
EP0381504A3 (en) Improvements in and relating to guanidine derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95195596.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SI SK TJ TT UA US US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2197466

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 970667

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 291479

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1995929155

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1997 776846

Country of ref document: US

Date of ref document: 19970514

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1995929155

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1995929155

Country of ref document: EP